Anti-aging research, supplements, and the science of living longer.
A landmark human trial reveals rapamycin's geroprotective effects through reduced cellular senescence in aging immune cells, while new research on immune system rejuvenation kicks off this month. Industry momentum accelerates with major biotech partnerships targeting Alzheimer's and neurodegenerative diseases, alongside emerging evidence on laser therapy for reversing skin aging markers.
Northeastern researchers revealed a new approach to identifying existing drugs that could impact aging by analyzing aging-related genes, while a fresh study from USC linked low-protein diets supplemented with amino acids to extended healthspan in mice. Meanwhile, a Boston biotech company has dosed the first human with a cellular reprogramming drug—marking a watershed moment in longevity intervention trials.
Cell reprogramming emerges as the dominant approach in longevity science following Life Biosciences' first human treatment injection for glaucoma. Meanwhile, rapamycin shows promise in clinical trials for muscle and bone health, while industry funding for reverse-aging startups accelerates with NewLimit's $435 million Series C round.
Cellular reprogramming moves from bench to bedside as Life Biosciences doses the first human with a vision-restoration therapy, while longevity biotech attracts record investment—NewLimit raises $435M at $3.1B valuation. Rapamycin shows promise for muscle and bone health in clinical trials, though recent analyses reveal limitations for healthy adults seeking lifespan extension.
Cellular reprogramming moves from lab to clinic as the first reverse-aging treatment is injected into a human patient, marking a watershed moment in rejuvenation medicine. Meanwhile, NewLimit secures $435 million ahead of clinical trials, and the CIAO Study convenes its 11th annual symposium to unveil new insights into longevity biology and healthy aging.
This week's longevity headlines are dominated by record-breaking funding announcements and emerging clinical evidence on aging reversal. NewLimit announced a staggering $435 million funding round after demonstrating age reversal in human liver cells, while peer-reviewed research confirms rapamycin extends lifespan comparably to caloric restriction. Harvard's public longevity report signals mainstream acceptance of the field.
Harvard publishes a major longevity report for general audiences signaling the field's maturation into mainstream science. Meanwhile, a San Antonio clinical trial is testing whether rapamycin can restore biological vitality in older adults, and five finalists have advanced in a prestigious longevity pitch competition spanning diverse interventions from ovarian aging to healthcare access.
This week's longevity research and industry landscape shows momentum in cellular reprogramming, clinical validation of rapamycin for muscle and bone health, and significant funding backing bold anti-aging ventures. Retro Biosciences reaches a $1.8 billion valuation while advancing Alzheimer's trials, and new findings on glycans offer potential aging reversal pathways.
This week in longevity science, a breakthrough study found that the senolytic drug ABT-263 dramatically accelerates wound healing in aged skin by clearing senescent cells, while a new editorial published in *Aging-US* calls for longevity interventions to be integrated into public health systems. Meanwhile, BioAge Labs attracted fresh analyst attention as investor enthusiasm in the longevity biotech sector continues to build, and billionaires including Jeff Bezos and Sam Altman are doubling down on aging-focused research companies.
This week in longevity science, fresh headlines from Longevity.Technology highlight a wave of clinical and biotech activity: new data from Cyclarity Therapeutics suggests atherosclerotic plaque damage may be reversible, fasting is gaining traction as a formal regenerative medicine intervention, and NMN supplementation is being studied specifically for menopausal energy decline. Meanwhile, Sam Altman–backed Retro Bio continues to attract attention for its convergence of cellular reprogramming and AI-driven protein design as it pursues one of the largest funding rounds in the sector.
This week's most significant longevity finding comes from the University of Rochester, where scientists successfully transferred a longevity-related gene from naked mole rats into mice, extending the rodents' lifespan and improving health outcomes. On the industry front, Altos Labs — the partial reprogramming biotech backed by billions in private capital — is stepping out of stealth mode, signaling a more public phase for one of the field's most closely watched companies. Clinical trial pipelines for rapamycin and senolytics continue to advance, though human evidence for life extension remains limited.
This week's most striking longevity headline comes from the University of Rochester, where scientists successfully transferred a longevity gene from naked mole rats into mice, extending their healthspan and lifespan. Meanwhile, Altos Labs — the $3 billion partial reprogramming company — is stepping out of stealth mode, and the longevity biotech pipeline continues to expand with new clinical trial activity in GLP-1 drugs, gene therapy, and NAD+ delivery platforms.
This week in longevity science, Altos Labs moves further out of stealth as partial reprogramming research accelerates toward potential clinical applications, while new clinical trial activity surfaces across Alzheimer's therapeutics, neurodegenerative disease, and immune resilience. A flurry of industry deals — including a $125 million immune resilience raise and a spermidine commercialization partnership — signals sustained investor appetite for longevity biotechnology even as the evidence base for popular interventions remains uneven.
This week in longevity science, new clinical and industry signals point to a maturing field: Buntanetap shows encouraging Alzheimer's trial results, a landmark deal brings spermidine into clinical settings, and Eli Lilly signals aggressive interest in longevity biotech ahead of a May 15 deadline. Meanwhile, FDA's "real-time trial" framework could reshape how anti-aging interventions are tested, and fresh research into sugar's role in skin aging opens new molecular targets for healthspan extension.
This week's biggest longevity story is rapamycin's surprising failure to enhance — and possible undermining of — exercise benefits, a finding that is reshaping how researchers think about the popular off-label drug. A sweeping New York Times Magazine deep-dive into cell rejuvenation science at Altos Labs examines whether partial reprogramming therapies could realistically reverse aging. Meanwhile, new research is challenging long-held assumptions about how much of our lifespan is actually written in our genes.
This week, a landmark New York Times investigation spotlights cellular rejuvenation biotech — including Altos Labs — as a potential path to reversing aging and curing hundreds of diseases. Business Insider profiles 11 rising stars reshaping longevity medicine as the field accelerates. Meanwhile, the longevity biotech and senolytic therapy market is projected to grow from $21.47 billion to $58.6 billion by 2034, signaling massive investor confidence in anti-aging science.
This week in longevity science, the FDA cleared the first cellular rejuvenation trial for human testing — a landmark regulatory moment for the reprogramming field. Researchers at Altos Labs saw a notable departure as a leading scientist defected to the Buck Institute, signaling ongoing tensions between commercial and nonprofit aging research. Meanwhile, new clinical data continues to refine our understanding of rapamycin, tozorakimab, and early-stage senolytic compounds across multiple active trials.
This week in longevity science, a fresh integrative genomics study in *npj Aging* identified new genetic and epigenetic drivers of biological aging, while the cellular reprogramming approach to age reversal moved closer to its first human trial. On the industry side, the longevity market attracted significant capital, with Life Biosciences landing $80M to advance cell-reset therapy and the sector broadly projected to reach $67B by 2035.
This week's longevity science landscape is shaped by a growing debate over whether aging should be classified as a treatable disease, fresh industry data projecting 2026 as a breakout year for longevity biotech investment, and continued scrutiny of AI's expanding role in drug discovery. Early brain screening, bioprinted organs, and human senolytic trials are generating headlines, while new surveys reveal that most Americans still fundamentally misunderstand what drives longevity.
This week in longevity research, experts convened to assess the state of senotherapeutics as a viable anti-aging strategy, while Human Longevity and the LEV Foundation launched a landmark centenarian blood study to map the biology of extreme healthy aging. Meanwhile, the longevity biotech sector continued to mature, with new analysis identifying AI-driven financial bottlenecks as an emerging challenge for getting therapies to patients.
Create custom signals on any topic. AI curates and delivers 24/7.
Create SignalPowered by
